




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Cardiac Surgery and VHD</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=f24e6d2b-ba21-4c56-871d-d44e86eba30b</link>
        <description>Clinical Topic Feed: Cardiac Surgery and VHD</description>
        <language>en</language>

        

                <item>
                    <title>PARTNER 3: 7-Year TAVR vs. SAVR Outcomes in Low-Risk Patients</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/PARTNER-3</link>                    <description>Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.</description>
                    <pubdate>1785862800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Indexing Ascending Aortic Dimensions to Height vs. Absolute Diameter to Identify High-Risk Patients</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/Indexing-Ascending-Aortic-Dimensions</link>                    <description>Indexing ascending aortopathy (AA) to height better identifies patients, especially women, who could benefit from earlier surgery rather than absolute diameters, according to a recent study published in JACC: Advances.</description>
                    <pubdate>1785325260000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC, SCAI and STS Submit Feedback on Proposed TAVR NCD</title>
<link>/Latest-in-Cardiology/Articles/2026/07/15/17/40/ACC-SCAI-and-STS-Submit-Feedback-on-Proposed-TAVR-NCD</link>                    <description>The ACC, along with the Society for Cardiovascular Angiography &amp;amp; Interventions (SCAI) and the Society of Thoracic Surgeons (STS), submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) on July 15 regarding the proposed decision memo for the National Coverage Determination (NCD) for TAVR.</description>
                    <pubdate>1784138100000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Clopidogrel vs. Aspirin Following PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM).</description>
                    <pubdate>1782910140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PARTNER 3: 7-Year Follow-Up Shows TAVR and Surgery Comparable in Low-Risk Patients With Symptomatic Severe AS</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/PARTNER-3</link>                    <description>TAVR and surgery demonstrated comparable and sustained valve durability in low-risk patients with symptomatic severe aortic stenosis (AS), with both approaches showing low and similar rates of structural valve deterioration (SVD), all-cause bioprosthetic valve failure (BVF) and reintervention through seven years...</description>
                    <pubdate>1782845400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PARTNER 2A, P2S3i Registry: 10-Year TAVR Outcomes With SAPIEN XT, SAPIEN 3</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/PARTNER-2A-P2S3i-Registry</link>                    <description>The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the PARTNER 2A trial, according to an analysis published June 16 in a valvular heart disease focus issue of JACC.</description>
                    <pubdate>1782399420000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>CMS Proposes Updates to TAVR National Coverage Determination</title>
<link>/Latest-in-Cardiology/Articles/2026/06/17/17/38/CMS-Proposes-Updates-to-TAVR-National-Coverage-Determination</link>                    <description>The Centers for Medicare and Medicaid Services (CMS) released a proposed decision memo on the National Coverage Determination (NCD) for TAVR, introducing changes to coverage pathways, evidence development and quality oversight.</description>
                    <pubdate>1781718060000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Feature | Navigating Valve Disease</title>
<link>/Latest-in-Cardiology/Articles/2026/06/01/01/Feature-Navigating-Valve-Disease</link>                    <description>Shared decision-making has become central to the management of valve disease, including tricuspid regurgitation (TR) (see cover story) and severe aortic stenosis (AS). If done correctly, it can help clinicians engage patients and families in meaningful discussions about symptoms, prognosis, treatment burden and personal goals...</description>
                    <pubdate>1780316280000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>The Evolut Low Risk Trial: Six-Year Outcomes of TAVR vs. SAVR in Patients at Low Surgical Risk</title>
<link>/Latest-in-Cardiology/Articles/2026/05/26/13/15/Evolut-Low-Risk-Trial-Six-Year-Outcomes</link>                    <description>The Evolut Low Risk trial was a prospective randomized trial that enrolled patients at low surgical risk with severe trileaflet aortic stenosis from 87 international sites between 2016 and 2019.</description>
                    <pubdate>1779899100000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Journals Science From EuroPCR 2026</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/18/18/10/JACC-Journals-Science-From-EuroPCR-2026</link>                    <description>Findings from four late-breaking clinical trials presented at EuroPCR 2026 in Paris, France, were simultaneously published in JACC: Cardiovascular Interventions. Together they lend new insights into residual tricuspid regurgitation (TR) after tricuspid valve transcatheter edge-to-edge repair (T-TEER), the safety of transfemoral (TF) transcatheter mitral valve replacement (TMVR), the novel BATMAN-TMVR technique, and the effect of implant depth on TAVR outcomes.</description>
                    <pubdate>1779371700000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>